Sobi® (STO: SOBI) today announced that data on Aspaveli/Empaveli in C3 glomerulopathy (C3G) and primary immune ...

Claseprubart achieved statistically significant and clinically meaningful improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL), ...

The trial tested two doses of claseprubart -- 300 mg and 600 mg -- and its primary endpoint was safety. Secondary outcomes included scores on the Myasthenia-Gravis Activities of Daily Living (MG-ADL) ...

Creative Biolabs expands its complement testing service, elevating sensitivity and efficiency for immunological research. Creative Biolabs' complement C1q binding assay enables scientists to determine ...

There is currently no cure for geographic atrophy (GA) – in other words, no effective therapy to entirely halt the disease process, restore vision or reverse the damage to the retina. Currently ...

Sobi® (STO: SOBI) today announced that data on Aspaveli/Empaveli in C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis ...

The complement receptor 1 (CR1) gene encodes a transmembrane glycoprotein that functions in the innate immune system. CR1 is expressed on blood cells and microglia. As a receptor for the complement ...

This fundamental study significantly advances our understanding of how parasites evade the host complement immune system. The new cryo-EM structure of the trypanosome receptor ISG65 bound to ...

This important study advances our knowledge of how parasites evade the host complement immune system. The new cryo-EM structure of the the trypanosome receptor ISG65 bound to complement component C3b ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye, and it marks the second of a three-part series on dry ...

The complement system identifies and eliminates pathogens and dying cells, 3 pathways can activate the complement system—classical, lectin, and alternative—and their activation results in similar ...